Background: Corticobasal syndrome (CBS) can harbor diverse pathologies, such as corticobasal degeneration (CBD) and Alzheimer's disease (AD). CSF biochemical analysis in CBS patients can confidently distinguish between an AD (CBS-AD) and a non-AD (CBS-nAD) pathology.
Objective: We utilized classical CSF biomarkers to make a distinction between the two groups and examine their clinical, neuropsychological, neuropsychiatric and imaging differences.
Methods: Seventeen patients with a CBS phenotype were included. Detailed clinical history, and neurological examination data were recorded. A thorough neuropsychological and neuropsychiatric test battery was performed, including Goldenberg apraxia test. Simple linear MRI measurements and planimetry data were utilized. CSF biomarkers for AD were ascertained.
Results: Five of seventeen CBS patients had a CSF AD profile. Patients with a CSF AD profile (CBS-AD; n = 5) were older and had a greater age at disease onset compared to CBS-nAD. CBS-AD patients had more frequently alien hand phenomena at examination and greater hippocampi surface asymmetry at MRI. CBS-nAD patients (n = 12) had lower superior colliculi width values.
Conclusion: Clinical, neuropsychological and imaging data cannot confidently differentiate CBS-AD from CBS-nAD patients.
Keywords: Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Corticobasal syndrome.
Copyright © 2019 Elsevier B.V. All rights reserved.